BioArctic AB (B9A.BE)
| Previous close | 16.62 |
| Open | 16.74 |
| Bid | 16.64 x 0 |
| Ask | 17.10 x 0 |
| Day's range | 16.60 - 16.91 |
| 52-week range | 15.70 - 32.58 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireBioArctic and Eisai sign research evaluation agreement regarding BAN2802
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that BioArctic AB and Eisai Co., Ltd., have entered into a research evaluation agreement regarding BAN2802, a potential new treatment combining BioArctic's proprietary BrainTransporter™ technology with an undisclosed Alzheimer drug candidate. At the end of the collaboration, Eisai will evaluate the data generated and decide if they chose to exercise an option to license BAN2802 for the treatment of Alzheimer's disease.
PR NewswireLecanemab deliberations at the CHMP regarding the Marketing Authorisation Application in the EU have been rescheduled due to procedural reasons
BioArctic AB:s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Oral Explanation scheduled for March 19 at the Committee for Medicinal Products for Human Use (CHMP) for lecanemab, which is currently under review by the European Medicines Agency (EMA), did not take place due to procedural reasons at EMA.
PR NewswireSales of Leqembi® totaled 1.1 billion yen in the fourth quarter 2023
BioArctic AB's (publ) (STO: BIOA-B) partner Eisai today issued their quarterly report containing Leqembi sales for the fourth quarter 2023 (third quarter of Eisai's fiscal year, ending March 2024). In total, sales of JPY 1.1 billion were recorded in the period, resulting in a royalty to BioArctic amounting to SEK 7.3 million.
